Hideaki Abe Selected Research

Papaverine

3/2021	A Unique Anti-Cancer 3-Styrylchromone Suppresses Inflammatory Response via HMGB1-RAGE Signaling.
12/2020	Trimebutine attenuates high mobility group box 1-receptor for advanced glycation end-products inflammatory signaling pathways.
1/2019	Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hideaki Abe Research Topics

Disease

9	Neoplasms (Cancer) 06/2021 - 03/2003
5	Glioma (Gliomas) 04/2021 - 04/2018
2	Sepsis (Septicemia) 10/2021 - 01/2019
2	Inflammation (Inflammations) 03/2021 - 12/2020
2	Carcinogenesis 03/2021 - 03/2003
2	Glioblastoma (Glioblastoma Multiforme) 03/2019 - 04/2018
2	Breast Neoplasms (Breast Cancer) 07/2005 - 03/2003
2	Carcinoma (Carcinomatosis) 07/2005 - 03/2003
1	Melanoma (Melanoma, Malignant) 01/2022
1	Hydrocephalus (Hydrocephaly) 04/2021
1	Infections 01/2019
1	Mental Disorders (Mental Disorder) 01/2017
1	Genomic Instability 01/2016
1	Hypoxia (Hypoxemia) 01/2013
1	Endometriosis 06/2010
1	Adenomyosis 06/2010
1	Endometrial Neoplasms (Endometrial Cancer) 09/2006
1	Prostatic Neoplasms (Prostate Cancer) 03/2003

Drug/Important Bio-Agent (IBA)

3	PapaverineIBA 03/2021 - 01/2019
3	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 03/2019 - 04/2018
2	Pharmaceutical PreparationsIBA 03/2021 - 02/2010
2	Receptor for Advanced Glycation End ProductsIBA 12/2020 - 01/2019
2	Temozolomide (Temodar)FDA LinkGeneric 01/2019 - 07/2018
2	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 06/2010
1	beta-thujaplicinIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	Monophenol Monooxygenase (Tyrosinase)IBA 01/2022
1	Microphthalmia-Associated Transcription FactorIBA 01/2022
1	TrimebutineIBA 10/2021
1	TNF-Related Apoptosis-Inducing LigandIBA 06/2021
1	TropoloneIBA 06/2021
1	Trypan Blue FDA Link 06/2021
1	Caspase 3 (Caspase-3)IBA 06/2021
1	2- (2- methoxy- 4- nitrophenyl)- 3- (4- nitrophenyl)- 5- (2,4- disulfophenyl)- 2H tetrazolium monosodium saltIBA 06/2021
1	Circulating Tumor DNAIBA 04/2021
1	Phosphotransferases (Kinase)IBA 03/2021
1	Interleukin-6 (Interleukin 6)IBA 03/2021
1	Nicotinamide PhosphoribosyltransferaseIBA 08/2020
1	Surface Antigens (Surface Antigen)IBA 03/2019
1	ErbB Receptors (EGF Receptor)IBA 03/2019
1	epidermal growth factor receptor VIIIIBA 03/2019
1	poly ADP-ribose glycohydrolaseIBA 01/2019
1	HMGB1 Protein (HMG1)IBA 01/2019
1	Histones (Histone)IBA 07/2018
1	alpha-hydroxyglutarateIBA 04/2018
1	NeuregulinsIBA 01/2017
1	Adenosine Diphosphate (ADP)IBA 01/2016
1	NAD (NADH)IBA 01/2016
1	Poly Adenosine Diphosphate RiboseIBA 01/2016
1	Small Interfering RNA (siRNA)IBA 05/2013
1	Messenger RNA (mRNA)IBA 01/2013
1	NG-Nitroarginine Methyl Ester (L-NAME)IBA 01/2013
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2013
1	CASP8 and FADD-Like Apoptosis Regulating Protein (FLIP-S)IBA 09/2006
1	CaspasesIBA 09/2006
1	Diphtheria ToxinIBA 07/2005
1	Lovastatin (Mevacor)FDA LinkGeneric 03/2003
1	Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)IBA 03/2003

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2019 - 01/2016
2	Therapeutics 07/2005 - 03/2003
1	Ventriculoperitoneal Shunt 04/2021
1	Ligation 01/2019
1	Punctures 01/2019
1	Chemoprevention 03/2003